Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Global X Genomics & Biotechnology ETF (NQ:GNOM)

8.940 +0.150 (+1.71%)
Streaming Delayed Price Updated: 10:02 AM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Global X Genomics & Biotechnology ETF

Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance
Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%. 
Via Benzinga
3 Gene Editing Stocks with Potential to Transform Medicine
Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. 
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today. 
Via InvestorPlace
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion. 
Via InvestorPlace
ETF Battles ARKG Vs. GNOM - What's The Better Genomic/Biotech Play?
Each ETF is judged against the other in key categories like cost, exposure strategy, performance, and a mystery category. 
Via Talk Markets
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks. 
Via InvestorPlace
3 Gene Editing Stocks With Unprecedented Surge Potential
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential. 
Via InvestorPlace
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example. 
Via InvestorPlace
3 Gene Editing Stocks to Generate Super-Charged Gains
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years. 
Via InvestorPlace
ETF Battles: Finding the Top Genomics Biotech ETF – A Triple Header of ARKG vs IDNA vs GNOM
The search for therapies tackling chronic illnesses like cancer, diabetes, and heart disease has put stocks in the biotechnology and genomics industry sector on center stage. 
Via Talk Markets
A Comprehensive Guide To Genomic ETFs
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
Top-Performing Biotech ETFs of Last Week
Investors may want to tap the bullishness in the biotech sector with the best biotech ETFs of last week. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.